Version 1
: Received: 27 August 2024 / Approved: 28 August 2024 / Online: 29 August 2024 (09:57:58 CEST)
How to cite:
Mirzaie, S.; Yuan, K. D.; Ni, H.; Wu, X. Y. Design of a Novel Multiepitope Vaccine against Glioblastoma by In-Silico Approaches. Preprints2024, 2024082058. https://doi.org/10.20944/preprints202408.2058.v1
Mirzaie, S.; Yuan, K. D.; Ni, H.; Wu, X. Y. Design of a Novel Multiepitope Vaccine against Glioblastoma by In-Silico Approaches. Preprints 2024, 2024082058. https://doi.org/10.20944/preprints202408.2058.v1
Mirzaie, S.; Yuan, K. D.; Ni, H.; Wu, X. Y. Design of a Novel Multiepitope Vaccine against Glioblastoma by In-Silico Approaches. Preprints2024, 2024082058. https://doi.org/10.20944/preprints202408.2058.v1
APA Style
Mirzaie, S., Yuan, K. D., Ni, H., & Wu, X. Y. (2024). Design of a Novel Multiepitope Vaccine against Glioblastoma by In-Silico Approaches. Preprints. https://doi.org/10.20944/preprints202408.2058.v1
Chicago/Turabian Style
Mirzaie, S., Heyu Ni and Xiao Yu Wu. 2024 "Design of a Novel Multiepitope Vaccine against Glioblastoma by In-Silico Approaches" Preprints. https://doi.org/10.20944/preprints202408.2058.v1
Abstract
Glioblastoma (GBM) is the most common malignant primary brain tumor, with a median survival rate of less than two years. Currently, there is no cure for GBM, underscoring the urgent need for innovative treatment approaches. Vaccine design emerges as a crucial strategy, offering a safe and effective means for both preventive and therapeutic interventions against GBM. In this study, we targeted four GBM-associated mutated surface proteins—urokinase plasminogen activator sur-face receptor (PLAUR), integrin beta-3 (ITGB3), and the B-41 alpha chain (HLA-B) and A-24 alpha chain (HLA-A) of the HLA class I histocompatibility antigens—to design a peptide-based vaccine. The vaccine construct includes cytotoxic T lymphocyte (CTL) and T helper cell (Th cell) epitopes, and was meticulously evaluated for antigenicity, allergenicity, and toxicity. The results indicate that the vaccine is antigenic and non-allergenic, making it a promising candidate. Additionally, the physico-chemical properties of the vaccine suggest stability and suitability for further de-velopment. Immune simulation studies predict efficient immune responses upon vaccine ad-ministration. Our vaccine shows promise as a potential tool in the fight against GBM, offering new hope for patients facing this devastating disease.
Keywords
Glioblastoma; vaccine; urokinase plasminogen activator surface receptor; Integrin beta-3; HLA class I
Subject
Biology and Life Sciences, Immunology and Microbiology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
